USFDA nod to Mylan and Biocon’s biosimilar of cancer drug Neulasta – ET HealthWorld

New Delhi: The US health regulator has approved Mylan’s cancer treating biosimilar Fulphila co-developed with Biocon, the companies said today. Fulphila is the first US Food and Drug Administration ( USFDA) approved biosimilar to Neulasta and the second biosimilar from Mylan and Biocon’s joint portfolio approved in the US, they said in a joint statement.

Categories: News Feed Tags: Tags: , ,

Categories: News Feed Tags: Tags: ,